While school districts around the country argue and debate over the mask mandate, on Monday, Pfizer announced that its COVID-19 vaccine, made by Pfizer and German partner BioNTech, effectively works in children 5 to 11. As of now, the vaccine is available for any person 12 and older. For some time, Pfizer has been testing the vaccine, at a much lower dose, on children, in a controlled setting, hoping to see positive results. Now, with President Joe Biden urging all Americans to do their part and get vaccinated, the drug company is claiming their controversial vaccine is safe for children. 

>>>>FOLLOW DREW CENSORSHIP-FREE ON TELEGRAM!<<<<

Talking to The Associated Press, Dr. Bill Gruber, senior vice president at Pfizer, said they tested the vaccine on elementary kids by giving them a third of the regular dose. The doctor excitedly revealed that just after the second dose, children between 5 and 11 had developed antibodies just as strong as teenagers to help fight the coronavirus. 

Go Ad-Free, Get Exclusive Shows and Content, Go Premium Today - $1 Trial

As for the side effects, due to the smaller dose, Gruber admitted they were only temporary, such as sore arms, achiness, or fever. He was sure to add, “I think we really hit the sweet spot.”

Pfizer CEO, Albert Bourla, was also excited about the news of the effectiveness of the vaccine in children. “Over the past nine months, hundreds of millions of people ages 12 and older from around the world have received our COVID-19 vaccine. We are eager to extend the protection afforded by the vaccine to this younger population, subject to regulatory authorization, especially as we track the spread of the Delta variant and the substantial threat it poses to children.”

***GET ON GETTR AND FOLLOW DREW HERE***

BioNTech’s co-founder and CEO, Dr. Ugur Sahin, didn’t miss out on the opportunity to share the news, saying, “The safety profile and immunogenicity data in children aged 5 to 11 years vaccinated at a lower dose are consistent with those we have observed with our vaccine in other older populations at a higher dose.” 

Go Ad-Free, Get Exclusive Shows and Content, Go Premium Today - $1 Trial

It should be noted, the findings from Pfizer have not been peer-reviewed. 

This piece was written by Jeremy Porter on September 20, 2021. It originally appeared in RedVoiceMedia.com and is used by permission.

The opinions expressed by contributors and/or content partners are their own and do not necessarily reflect the views of DrewBerquist.com. Contact us for guidelines on submitting your own commentary.